Future University is one of most promising private universities in Egypt. Through excellence in teaching, research and service, Future University strives to provide a comprehensive, high-quality education that prepares our graduates to be future leaders.
90th Street
New Cairo

Mona El Assal

Basic information

Name : Mona El Assal
Title: Associat Professor of Pharmaceutics at Pharmaceutics and Pharmaceutical Technology department at FUE University.
Google Schoolar Link
Personal Info: Dr. Mona Ebrahim. Associat Professor of Pharmaceutics at Pharmaceutics and Pharmaceutical Technology department.She got her Master and Doctoral degree from Cairo University View More...


Certificate Major University Year
PhD Pharmaceutics and Clinical Pharmacy. Cairo University 2005
Masters Pharmaceutics and Clinical Pharmacy. Cairo University. 2000
Bachelor Pharmaceutical Sciences Cairo University 1984

Teaching Experience

Name of Organization Position From Date To Date
Military Medical Academy Consultant of Army Pharmaceutical Industry and Lecturer 01/01/1992 01/01/2011

Researches /Publications


Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona Ibrahim Abdel Tawab El-assal


Background Topical treatment of skin diseases needs to be strategic to ensure high drug concentration in the skin with minimum systemic absorption. The present investigation was enthused by the possibility to develop solid lipid nanoparticles (SLNs) of hydrophilic drug acyclovir. Also study vitro and vivo drug delivery. Methods: Acyclovir loaded solid lipid nanoparticles were prepared by high pressure homogenization of aqueous surfactant solutions containing the drug-loaded lipids in the melted or in the solid state with formula optimization study. Acyclovir loaded solid lipid nanoparticles were incorporated in cream base. The pH was evaluated and rheological study. Drug release was evaluated and compared with drug based on simple cream. Also the release of acyclovir loaded solid lipid nanoparticles conjugate with compritol 888ATO was compared with marketed cream. The potential of solid lipid as the carrier for dermal delivery was studied. Results: Particle size analysis of SLNs prove small, smooth, spherical shape particle ranged from 150 to 200 nm for unloaded and from 330 to 444 nm for acyclovir loaded particles. The EE% for optimal formula is 72% with suitable pH for skin application. Rheological behavior is shear thinning and thixotropic. Release study proved controlled drug release especially in formula containing compritol88 ATO. Stability study emphasized an insignificant change in the particles properties over 6 month. Invivo study showed significantly higher accumulation of acyclovir in stratum corneum compared with blank skin. Conclusion: acyclovir loaded solid lipid nanoparticles might be beneficial in controlling drug release, stable and improving dermal delivery of antiviral agent(s)

Download PDF
Formulation, Optimization, and Evaluation of Solid Dispersions of metformin HCl Using Factorial Design - 01/1

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona El Assal, Mohammed mannaa, Ahmed Abdel Bary,


ABSTRACT The objective of this study is to achieve the controlling dissolution rate of Metformin HCl, a freely water soluble antidiabetic drug. Solid dispersions microcapsules were prepared using solvent evaporation method which enclosed preparation of a uniform dispersion of Metformin HCl in (Hydroxy propyl methylcellulose k100, Ethyl cellulose, Eudragit RL PO, RS PO & Compritol 888 ATO). A two-factor, General factorial statistical design was used to quantitate the effect of polymer type (X1) and drug: polymer ratio(X2) on the release profile. Where polymer type and drug: polymer ratio were selected as independent variables, while Y1 (cumulative drug release after 1 hr. ) and Y2 (cumulative drug release in 3 hrs. ), Y3 (cumulative drug release in 10 hrs.),Y4 (angle of repose ) and Y5 (Hausner ratio) were selected as dependent variables. The solid dispersions were characterized for their in vitro- release rate. The optimized formulation was further characterized by Drug scanning calorimetry, infrared spectrophotometry, X-Ray Diffractometer and SEM analysis. A convenient statistical model was made and a significantly controlled release rate was exhibited .the optimized formulation was investigated by DSC, XRD, FTIR and SEM data which showed the crystalline nature of Metformin HCl in a solid dispersion, the statistical model helped us to recognize the effects of formulation variables on the dispersion. Keywords: Metformin HCl, Solid dispersion, controlled release, factorial design, HPMC k 100, Ethyl cellulose, Eudragit RL, RS& Compritol ATO 888.

Download PDF
Gelatine Based Nanoparticles as Drug Delivery System of Lornoxicam Gel - 01/1

Mona Ebrahim Abdel Tawab Ahmed Elassal


Abstract: The purpose of contemporary study was to project GNP by using of two step desolvation method. Biodegradable hydrophilic gelatin nanoparticles used as a delivery system of anti-inflammatory lornoxicam after gel formulation using each of hydroxyl propyl methyl cellulose (HPMC) and carbopol as gelling agent. The size and shape of the nanoparticles were examined by optical microscope and transmission electron microscopy, particles with a mean diameter of 240.6 nm and 0.1 poly dispersibility index PDI were produced and the percentage of entrapment efficiency was found to be 87.1%. The optimum amount of LOR loading was obtained. Four formulas were prepared F1 standard LOR carbopol gel, F2 standard LOR HPMC gel, F3 GNP –LOR containing carbopol as gelling agent and F4 GNP –LOR which has HPMC as gelling agent are GNP-LOR gel. Permeation of drug through membrane was determined by Franz diffusion cell. Further stability studies were carried out at 4Co for a period of 8 weeks. Vivo study was carried on white albino male rats to compare between different lornoxicam gel formulations. Conclusion: Results show that the two step desolvation is an appropriate method for preparing GNP. LORF3 which has carbopol as gelling agent was of lower release rate with maximum % inhibition of edema.

Download PDF
Effect of Tinidazole on Norfloxacin Disposition - 01/0

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona Ibrahim Abdel Tawab El-Assal Sally Ahmed Helmy


Background: Co-administration of norfloxacin (NFX) and tinidazole (TNZ) has been used for the treatment of gastrointestinal and urinary tract infections. Concomitant oral administration of NFX with TNZ may affect NFX absorption and consequently its blood concentration and pharmacological effect. Objective: The present study was undertaken to investigate the effect of TNZ at the usual clinical dosage on the pharmacokinetics of NFX in healthy volunteers. Methods: This study was conducted as an open-label, randomized, two-way crossover experimental design. After an overnight fast, subjects were randomized to receive a single oral dose of NFX 400 mg alone and the fixed-dose combination (FDC) of NFX /TNZ 400 mg/600mg on two different occasions separated by 1-week washout period between treatments. Blood samples were collected up to 24 hours postdose, and plasma was analyzed for NFX concentrations by using HPLC. The pharmacokinetic properties of NFX after FDC administration were compared with NFX administered alone. Results: Twelve healthy subjects were enrolled (6 in each part), and all subjects completed the study. None of the participants showed any sign of adverse drug reactions during or after the completion of the study. The 90% confidence interval (CI) between NFX alone and when co-administered with TNZ indicated the presence of an interaction between NFX and TNZ, which would significantly increase the systemic rate and exposure of NFX absorption. The co-administration of TNZ with NFX increased the AUC and C compared with administration of NFX alone. The AUC and C max max of NFX significantly of NFX alone were 6.0 µg.hr/mL (2.3-9.8) and 0.87 µg/mL (0.4-1.6), respectively whereas, the corresponding AUC and C administration of FDC were 7.1 µg.hr/mL (4.0-10.6) and 0.97 µg/mL (0.4-1.7), respectively. The respective geometric mean ratios of NFX for AUC and C max 1.522] and 1.087 (90% CI, 0.807 -1.463) compared with NFX alone. Both T max values after with TNZ were 1.197 [90% CI, 0.941- max and Ka of NFX showed a significant decrease after administration of the combination compared to administration of NFX alone. The peak plasma concentration reached at 1.3 h (0.6-2.4) and 1.9h (0.4-4.4) after oral administration of FDC and NFX alone, respectively. Conclusions: Both NFX and TNZ were well tolerated. The interaction of TNZ with fluroquinolones should be investigated to determine whether this interaction is limited to NFX or if other fluroquinolones have the same pharmacokinetic interactions. Further studies are necessary to determine 2 the role of P-gp and other transporters on NFX disposition and pharmacokinetics. Additionally, the influence of TNZ on the physiological activity of GIT should be investigated.

Download PDF
Single dose Linezolid Pharmacokinetics in ill Patienys with Impaired Renal Function Epecially Chronic Hemodialysis Patients - 01/0

Mona Ebrahim Abdel Tawab Ahmed Elassal


ABSTRACT: Background and Objective: Renal failure patients were treated with linezolid (LZD) for proven or suspected infections by multi-resistant Gram-positive cocci. The aim of this study was to determine if dose adjustment of LZD is needed as a function of renal impairment or not, especially that a significant component of LZD is eliminated unchanged in urine. Methods: The single dose pharmacokinetics of LZD was investigated. Eighteen non-infected male subjects with various degrees of renal impairment ranged from normal to severe chronic impairment were enrolled, including end-stage renal disease (ESRD) patients maintained on hemodialysis (HD). LZD was administered as a single oral 600mg dose, and blood samples were drawn at different times and analysed by a validated HPLC assay method. Plasma profiles were evaluated by non-compartmental and compartmental approaches. Results and Discussion: A similar rate and extent of LZD absorption and elimination and comparable body exposure was observed in both healthy subjects and acute renal failure patients. The extent of LZD exposure was significantly increased by 3-fold in ESRD patients in their off-dialysis day. Furthermore, the t1/2 and MRT values were significantly increased by ~5- and 3-fold, respectively. The Vd/F values of LZD did not change with renal function. A significant decrease in CL/F by ~3-fold was observed in ESRD patients in their off-dialysis day however, CL/F was significantly increased by ~4-fold during HD. Approximately half of the administered LZD dose was removed during the HD session in these selected cohorts of ESRD patients. LZD was generally well tolerated. Conclusions: The dose of LZD did not need to be adjusted for patients with acute renal dysfunction or ESRD on HD. One of the twice-daily doses should be administered after the dialysis session because almost half of the LZD dose was substantially removed by HD. During the first three dialysis sessions of the treatment course, to avoid potentially ineffective therapy, a supplemental dose of LZD might be given if necessary or the dose of LZD should be administered 4 h before the beginning of the HD session. This was to keep LZD levels above the MIC for the organism causing the infection being treated.

Download PDF


Award Donor Date
Certificate of Excellence Meletary Medical Services 2005

Follow us on

Visit the Faculty